Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Wellness Wire Kansas.
Press releases published on August 14, 2025
Milestone Scientific Achieves 25% Increase in Revenue for the Second Quarter of 2025
GlobeNewswire
·
August 14, 2025
ROSELAND, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provides a business update and reported financial …
BioStem Technologies Reports Preliminary Second Quarter 2025 Financial Results
GlobeNewswire
·
August 14, 2025
POMPANO BEACH, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for …
Shuttle Pharma Provides Second Quarter 2025 Corporate Update
GlobeNewswire
·
August 14, 2025
GAITHERSBURG, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer …
CMMB, with P&G Support, Responds to Deadly Cholera and Hunger Crisis in South Sudan
GlobeNewswire
·
August 14, 2025
Juba, South Sudan, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Catholic Medical Mission Board (CMMB) is launching an emergency response in South Sudan as compounding crises threaten thousands of lives in Upper Nile region and Central Equatoria State. The devastating …
Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
GlobeNewswire
·
August 14, 2025
Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at closing and is eligible to receive up to an additional $4.8 million under a contingent value right (CVR), plus a 2.5% royalty on future net sales of …
Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 14, 2025
Next-generation claudin 18.2 ISAC BDC-4182 now in Phase 1 dose-escalation study Cash balance of $48.5 million as of June 30, 2025 anticipated to fund key milestones through mid-2026 REDWOOD CITY, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Bolt …
GT Biopharma Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 14, 2025
GTB-3650 TriKE® Phase 1 trial has successfully completed Cohort 1 and Cohort 2 dosing, treating a total of four patients; following Cohort 2’s formal safety review, it has advanced into Cohort 3 and initiated dosing of the fifth patient in the study; …
Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 14, 2025
– Phase 1 monotherapy expansion study of micvotabart pelidotin (MICVO) for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients progressing well with preliminary data in second half of 2025 and first half of 2026 – Phase 1/ …
CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights
GlobeNewswire
·
August 14, 2025
Presented positive translational data from SYNGAP1-related disorders program showcasing efficacy in a humanized SYNGAP mouse model and increased protein in non-human primates at the 28th American Society of Gene and Cell Therapy (ASGCT) Annual Meeting …
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2025
GlobeNewswire
·
August 14, 2025
PORTLAND, Maine, Aug. 14, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the …
Venus Concept Announces Second Quarter 2025 Financial Results
GlobeNewswire
·
August 14, 2025
TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and six months ended June 30, 2025. Summary of …
Nasus Pharma Announces Closing of Initial Public Offering
GlobeNewswire
·
August 14, 2025
TEL AVIV, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions …
Glucotrack Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
GlobeNewswire
·
August 14, 2025
On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025 Investigational Device Exemption submission to FDA of novel CBGM technology in Q4 …
Elutia Delivers Robust Growth on the Strength of EluPro™ Market Adoption
GlobeNewswire
·
August 14, 2025
EluPro™ Q2 revenue up 49% sequentially; Elutia advances next-generation drug-eluting biomatrix for breast reconstruction Conference call today at 5:00 p.m. ET / 2:00 p.m. PT GAITHERSBURG, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“ …
TOMI Environmental Solutions, Inc. Reports Q2 2025 Financial Results and Outlines Growth Initiatives
GlobeNewswire
·
August 14, 2025
FREDERICK, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ), a global provider of disinfection and decontamination essentials through its premier Binary Ionization Technology® (BIT™) platform, today announced …
Profound Medical Announces Second Quarter 2025 Financial Results
GlobeNewswire
·
August 14, 2025
TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation …
RxSight, Inc. to Present at the Wells Fargo Healthcare Conference
GlobeNewswire
·
August 14, 2025
ALISO VIEJO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming …
IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights
GlobeNewswire
·
August 14, 2025
Announced clinical improvement in progression free survival observed in pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (pembrolizumab) for the treatment of first-line advanced melanoma, but statistical significance narrowly missed; company plans to meet …
CapsoVision Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 14, 2025
SARATOGA, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for its second …
Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
GlobeNewswire
·
August 14, 2025
Tanruprubart (formerly ANX005) for GBS Advancing Through Regulatory Interactions; MAA Submission in Europe Anticipated in First Quarter of 2026; Ongoing Discussions with FDA Regarding Generalizability Package to Support a BLA Accelerated Completion of …